InvestWiserImmunovia publ AB
IMMNOV · Nasdaq Stockholm · Healthcare
0.08SEK
−10.6%last day
Price as of 2 October 2026
Performance
1 month
−42.3%
1 year
−80.5%
3 years, per year
−37.1%
5 years, per year
−71.9%
Largest fall, 3 years
−99.7%
Below the peak now
−99.9%
Volatility, 1 year
103.5%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
2.1
Dividend yield
0.0%
Return on equity
−373.7%
Net margin
−171.6%
Market value
5 m USD
Quality, value and trend
Where Immunovia stands against every Nordic stock today. 100 is best.
61
Profitability and a sound balance sheet over time. Better than 61% of Nordic stocks.
15
The price measured against earnings, assets and cash flow. Better than 15% of Nordic stocks.
2
The price development over the past year. Better than 2% of Nordic stocks.
9
Quality, value and trend together. Better than 9% of Nordic stocks.
About Immunovia
Immunovia publ AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 18 employees.
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis